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  Abstract  
 
The menace of Coronavirus Disease-19 (COVID-19) has made life more and more challenging throughout the world. 
Amidst these difficult times, doctors have proved their exceptional worth. They have performed their duties with 
notable dedication, diligence, resilience, and compassion. Here we share our experiences from the State of Rajasthan 
in Northern India. We were benefitted by very early lockdown by the government, preventive strategies of containment, 
and the most effective contact tracing program. The creation of hundreds of surveillance teams and rapid response 
teams (RRT) was instrumental for the containment program. This was coupled with outstanding medical care 
exemplified by Sawai Man Singh Medical College Hospital (SMSMCH) at Jaipur, the capital city of Rajasthan. The 
mortality rate-limiting to 1.98% in Rajasthan has been an outcome of the amalgamation of brisk administrative action, 
government support, and visionary action and the best of health care facilities. Our COVID-19 management program 
strategy was based on the advanced treatment guidelines from the Indian Council of Medical Research, New Delhi, 
India, and the Ministry of Health and Family Welfare, Government of India.  
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Background  
The specter of Coronavirus Disease-19 (COVID-19) defying 
and flouting all time and geographic locale precepts have 
bemused humanity across the globe. An onerous challenge that 
specialists in Medical Science took spearheading the mission 
with evident dedication, diligence, resilience, and compassion 
to break into the esoteric code of Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2). It would be 
worthwhile to add that the State of Rajasthan in Northern India 
was very ably supported by timely and meticulous Government 
preventive containment strategies of early lockdown with 
timely effective contract tracing program inclusive of the 
genesis of adequate surveillance rapid response teams (RRT) 
along with exemplary medical care, an essential feature of 
policy-making the edifice of which was drafted by Sawai Man 
Singh Medical College Hospitals (SMSMCH) at Jaipur, a 
premier Tertiary Care Medical Institute of Asia. 
    To achieve the best results in treatment outcome, it is prudent 
to address the disease process in its infancy with the premise to 
nip through a proactive investigative armamentarium with 
customized management protocol to be initiated in the prescient 
early stage of the disease. An aggressive protocol was designed 
for mild to the moderately severe disease process of COVID-19, 
wherein the reported axes of the disease were assessed namely, 
coagulopathy through D-dimers and fibrinogen degradation 
products (FDPs) levels in serum, cytokine storm, and 
inflammatory overdrive through varied markers of 
Neutrophilic/Lymphocytic ratio (N/L ratio), C-Reactive Protein 
(CRP), Interleukin-6 (IL-6), Tumor Necrosis Factor (TNF) and 
Interleukin-1 (IL-1) assay, the cardiac evaluation was done 
through color Doppler, and the lungs were assessed through 
HRCCT, Pulmonary CT Angiography and Point of Care 
Ultrasonography (POCUS) in those patients who could not be 
mobilized to High-resolution chest computed tomography 
(HRCCT) [1].  A need-based utility management approach was 
strategized in the initial stages of the disease that included 
SARS-CoV-2 portal of entry blocker namely 
hydroxychloroquine (HCQ), anti-viral drugs of lopinavir, 
ritonavir and remdesivir, steroids in acute respiratory distress 
syndrome (ARDS), low-molecular-weight heparin in 
Pulmonary thromboembolic phenomenon and tocilizumab in 
the documented picture of cytokine storm along with 
administration of convalescent plasma when endogenous 
antibody response to the virus is still in nascence in the wide-
spectral COVID-19.  
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Such a proactive, aggressive clinical approach was instrumental 
in keeping the case and case fatality rates low along with 
decreased chances of mortality in patients with existing co-
morbid conditions. 
     The stratagem so conscripted acted as a fountainhead for the 
State with the creation of dedicated COVID-19 Center of 300 
bedded ICU and thousand bedded IPD along with separate 
COVID-19 OPD and observation ward for suspected patients. 
For critically ill patients, Infectious Diseases Hospital (IDH) 
was fully equipped with highbred ICU facilities. During the 
pandemic's peak, average 500 plus patients were admitted to the 
Institute from asymptomatic category to severe category. The 
extraordinary cure rate of 73.27% and mortality rate-limiting to 
1.98% in Rajasthan was an outcome of the amalgamation of 
brisk administrative action, outstanding government support, 
and advanced visionary action with state-of-art medical 
facilities [2]. The COVID-19 management program was 
developed on extensive logistic deliberations based on evolving 
treatment guidelines from Indian Council of Medical Research, 
New Delhi, India and Ministry of Health and Family Welfare, 
Government of India [3] inclusive of early proactive work up 
with aggressive treatment at Sawai Man Singh Medical College 
Hospitals (SMSMCH), Jaipur. The COVID-19 management 
protocol was designed according to the severity scale, managing 
aggressively mild to moderate disease, and addressing cytokine 
storm in COVID-19 patients that gave appreciable outcomes. 
SMSMCH is one of the pioneers in COVID-19 plasma therapy 
and is part of the WHO solidarity trial, [4, 5] with an emphasis 
on bringing down the mortality rate and increasing recovery 
rate as part of various measures to contain COVID-19. 
 
Conclusion  
The measures inclusive of Government, Societal and Medical, 
so outlined, were able to curtail the COVID-19 pandemic to 
some extent in our State. There are ongoing efforts to address 
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